We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

BRAIN Biotech AG (BNN) NPV

Sell:€3.33 Buy:€3.51 Change: €0.27 (7.50%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€3.33
Buy:€3.51
Change: €0.27 (7.50%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:€3.33
Buy:€3.51
Change: €0.27 (7.50%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

Contact details

Address:
Darmstaedter Strasse 34-36
ZWINGENBERG
64673
Germany
Telephone:
+49 (6251) 93310
Website:
https://www.brain-biotech.com/de

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BNN
ISIN:
DE0005203947
Market cap:
€77.12 million
Shares in issue:
21.85 million
Sector:
Specialty Chemicals
Exchange:
Frankfurt Stock Exchange
Country:
Germany
Currency:
Euro
Indices:
n/a

Key personnel

  • Michael Majerus
    Independent Chairman of the Supervisory Board
  • Adriaan Moelker
    Chairman of the Management Board, Chief Executive Officer
  • Anna Eichhorn
    Independent Deputy Chairman of the Supervisory Board
  • Michael Schneider
    Chief Financial Officer, Member of the Management Board
  • Michael Krohn
    Member of the Senior Management, Executive Vice President, Head of Research & Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.